Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes

Anti-Cancer Drugs

Volumn 26, Issue 7, 2015, Pages 706-715

  Zhang, Hui ^a   Jing, Xuanxuan ^a   Wu, Xiaojuan ^a   Hu, Jing ^a   Zhang, Xiaofang ^a   Wang, Xiao ^a   Su, Peng ^a   Li, Weiwei ^a   Zhou, Gengyin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

FZD1; Multidrug resistance; Ovarian cancer; Rosiglitazone; Wnt catenin

Indexed keywords

BETA CATENIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FRIZZLED PROTEIN; FRIZZLED PROTEIN 1; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTINEOPLASTIC AGENT; FZD1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; WNT PROTEIN;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; FEMALE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; MULTIDRUG RESISTANCE; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; ACTIVE TRANSPORT; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL NUCLEUS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANILIDES; ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FRIZZLED RECEPTORS; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; WNT PROTEINS;

EID: 84942764742     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000236     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
3. Gao P, Zhou GY, Guo LL, Zhang QH, Zhen JH, Fang AJ, Lin XY. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter. Cancer Lett 2007;256:81-89.
4. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-516.
5. Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol 2010;6:527-537.
6. Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review. Taiwan J Obstet Gynecol 2009;48:239-244.
7. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-171.
8. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
9. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
10. Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, Norris MD. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer 1997;33:2031-2036.
11. Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 2007;98:1303-1310.
12. Ludwig JA, Szakacs G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 2006;66:4808-4815.
13. Fusi F, Saponara S, Valoti M, Dragoni S, D'Elia P, Sgaragli T, et al. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives. Curr Drug Targets 2006;7:949-959.
14. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861-879.
15. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 2008;4:205-223.
16. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008;18:954-962.
17. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000;60:4761-4766.
18. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006;16:51-59.
19. Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H, et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/beta-catenin pathway. Cancer Lett 2012;323:106-113.
20. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001;7:395-400.
21. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 2004;4:465-477.
22. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003;9:1-9.
23. Lu D, Carson DA. Repression of beta-catenin signaling by PPAR gamma ligands. Eur J Pharmacol 2010;636:198-202.
24. Knipper R, Kuehlcke K, Schiedlmeier B, Hildinger M, Lindemann C, Schilz AJ, et al. Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Ther 2001;8:239-246.
25. Gao P, Zhou GY, Zhang QH, Li H, Mu K, Yuan YP, et al. Reversal MDR in breast carcinoma cells by transfection of ribozyme designed according the secondary structure of mdr1 mRNA. Chin J Physiol 2006;49:96-103.
26. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803.
27. Tomkova K, Belkhiri A, El-Rifai W, Zaika AI. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res 2004;64:6390-6393.
28. Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 2002;22:1-23.
29. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 2005;92:113-119.
30. Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents. Cancer Ther 2008;6(A):25-34.
31. Mustafa A, Kruger WD. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res 2008;14:4935-4942.
32. Panigrahy D, Shen LQ, Kieran MW, Kaipainen A. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 2003;12:1925-1937.
33. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004;5:419-429.
34. Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, et al. The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. Biotechnol Adv 2012;30:169-184.
35. Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, et al. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-gamma (PPAR-gamma): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta 2014;1845:42-52.
36. Dicitore A, Caraglia M, Colao A, Zappavigna S, Mari D, Hofland LJ, et al. Combined treatment with PPAR-gamma agonists in pancreatic cancer: a glimmer of hope for cancer therapy? Curr Cancer Drug Targets 2013;13:460-471.
37. Zhang L, Xue Y, Jiang B, Strouthos C, Duan Z, Wu Y, et al. Multiscale agentbased modelling of ovarian cancer progression under the stimulation of the STAT 3 pathway. Int J Data Min Bioinform 2014;9:235-253.
38. Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/betacatenin pathway in ovarian cancer: a review. Gynecol Oncol 2013;131:772-779.
39. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 2002;99:13771-13776.
40. Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook AL, Boyle GM, et al. PPARgamma agonists attenuate proliferation and modulate Wnt/betacatenin signalling in melanoma cells. Int J Biochem Cell Biol 2009;41:844-852.
41. Szentandrassy N, Harmati G, Barandi L, Simko J, Horvath B, Magyar J, et al. Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells. Br J Pharmacol 2011;163:499-509.
42. Chou YY, Jeng YM, Kao HL, Chen T, Mao TL, Lin MC. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology 2003;43:151-156.